PATIENT-REPORTED OUTCOME MEASURES IN PATIENTS WITH POLYCYTHEMIA VERA AND ESSENTIAL THROMBOCYTHEMIA TREATED WITH RUXOLITINIB OR BEST AVAILABLE THERAPY IN THE RANDOMIZED PHASE 2B RUXOBEAT CLINICAL TRIAL

Authors
Category Primary study
Conference31st Congress of the European Hematology Association Congress, EHA 2026
Year 2026
This article has no abstract
Epistemonikos ID: 16300a0c8a15014fb9a9d25cb3aeaeb380010fbb
First added on: Aug 08, 2026